Medicare to Cover Myriad Genetics’ BRACAnalysis for FDA-Approved CDx Indications

The Centers for Medicare & Medicaid Services will now cover Myriad Genetics’ BRACAnalysis CDx when used to identify prostate cancer patients with germline BRCA1 and BRCA2 mutations who may benefit from the PARP inhibitor olaparib (AstraZeneca/Merck’s Lynparza).

Medicare contractors partaking in the MolDx program — Palmetto, CGS Administrators, Noridian, and Wisconsin Physicians Service Insurance Corporation — all recently issued local coverage articles that now list the four tumor types for which olaparib is approved alongside BRACAnalysis CDx as a companion diagnostic, including  breast, ovarian, pancreatic, and prostate cancer. The article also notes that the test is a covered companion diagnostic for not just olaparib in these settings, but other FDA-approved PARP inhibitors, such as talazoparib (Pfizer’s Talzenna) and Rubraca (Clovis Oncology’s rucaparib), in breast and ovarian cancer.  

Source: https://www.genomeweb.com/reimbursement-news/medicare-cover-myriad-genetics-bracanalysis-fda-approved-cdx-indications